A Phase 1 interventional study of Clarithromycin and Zidovudine in Mycobacterium Avium-intracellulare Infection and HIV Infections, sponsored by Abbott. Completed at 2 sites in United States. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2008-08-04.
Sponsored by Abbott · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Mycobacterium avium-intracellulare Infection · United States.
Among the 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States, this one is the 30th largest by enrollment of the 37 interventional ones that give a count, is one of 7 in phase 1, and was the 1st registered.
66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.
Browse Mycobacterium avium-intracellulare Infection studies →3 of the 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+
Chris Goss · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages up to 100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Mycobacterium avium-intracellulare Infection studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 3 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 11 · Phase 4 3
First in 1984; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 95 across 44 interventional studies indexed under Mycobacterium avium-intracellulare Infection.
Median enrollment 100 across the 37 interventional studies, 50 across the 5 observational. Of the 48 that completed or were terminated, 4 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 52 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 1 study filed under Mycobacterium avium-intracellulare Infection — fewer than ten, so there is no comparison to draw.
1 of the studies in Mycobacterium avium-intracellulare Infection with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04294043Chris GossIV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 52 studies in Mycobacterium avium-intracellulare Infection with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy.
Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.
Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.
Patients that are included are HIV infected and have started zidovudine (AZT) or didanosine (ddI) at least 4 weeks before entry into this study. Patients continue taking the medications at prescribed doses. In addition they also take clarithromycin. Patients continue treatment with AZT or ddI plus clarithromycin for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Prior Medication: Required:
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 30 days of study entry:
Active alcohol or drug use sufficient in the opinion of the investigator to prevent adequate compliance with medication regimen and clinic visits.
This study is completed, as verified in Oct 1996. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clarithromycin · Zidovudine
Mycobacterium avium-intracellulare Infection →